Details of the Drug

General Information of Drug (ID: DMIZ6W2)

Drug Name
Norfloxacin
Synonyms
Baccidal; Barazan; Chibroxin; Fulgram; Lexinor; NFLX; Norflo; Norfloxacine; Norfloxacino; Norfloxacinum; Noroxin; Sebercim; Merck Brand of Norfloxacin; Norfloxacin Merck Brand; AM 0715; AM 715; AM0715; MK 0366; MK 366; MK0366; MK366; AM-0715; AM-715; Chibroxin (TN); Insensye (TN); MK-0366; MK-366; Norflohexal (TN); Norfloxacine [INN-French]; Norfloxacino [INN-Spanish]; Norfloxacinum [INN-Latin]; Norfocin (TN); Noroxin (TN); Nufloxib (TN); Roxin (TN); Utin (TN); Utinor (TN); Apo-Norflox (TN); Norfloxacin (JP15/USP/INN); Norfloxacin [USAN:BAN:INN:JAN]; Chibroxin, MK-366, Baccidal, Sebercim, Zoroxin, Norfloxacin; 1,4-Dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinoline-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
Indication
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [1]
Therapeutic Class
Antibiotics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 319.33
Topological Polar Surface Area (xlogp) -1
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
Absorption
The drug is rapidly absorbed [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 3 - 4 hours [3]
Metabolism
The drug is metabolized via the liver [2]
Chemical Identifiers
Formula
C16H18FN3O3
IUPAC Name
1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
Canonical SMILES
CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O
InChI
InChI=1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23)
InChIKey
OGJPXUAPXNRGGI-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4539
ChEBI ID
CHEBI:100246
CAS Number
70458-96-7
DrugBank ID
DB01059
TTD ID
D0Q2PE
VARIDT ID
DR01204
INTEDE ID
DR1176
ACDINA ID
D00479

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU; GYRB_STAAU Modulator [4]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [5]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [6]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 1A2 (CYP1A2)
Main DME 		DEJGDUW CP1A2_HUMAN Substrate [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Norfloxacin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Clarithromycin. Bacterial infection [1A00-1C4Z] [48]
Coadministration of a Drug Treating the Disease Different from Norfloxacin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Norfloxacin and Ivosidenib. Acute myeloid leukaemia [2A60] [49]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Midostaurin. Acute myeloid leukaemia [2A60] [48]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Idarubicin. Acute myeloid leukaemia [2A60] [48]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Arn-509. Acute myeloid leukaemia [2A60] [50]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Gilteritinib. Acute myeloid leukaemia [2A60] [51]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Norfloxacin and Ivabradine. Angina pectoris [BA40] [50]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Norfloxacin and Bepridil. Angina pectoris [BA40] [52]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Norfloxacin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [53]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Cilostazol. Arterial occlusive disease [BD40] [48]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Posaconazole. Aspergillosis [1F20] [48]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Norfloxacin and Levalbuterol. Asthma [CA23] [54]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Norfloxacin and Pirbuterol. Asthma [CA23] [54]
Aminophylline DML2NIB Moderate Decreased metabolism of Norfloxacin caused by Aminophylline mediated inhibition of CYP450 enzyme. Asthma [CA23] [55]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [50]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Desipramine. Attention deficit hyperactivity disorder [6A05] [48]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Retigabine. Behcet disease [4A62] [56]
Lomustine DMMWSUL Minor Decreased absorption of Norfloxacin due to intestinal mucosa variation caused by Lomustine. Brain cancer [2A00] [57]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Eribulin. Breast cancer [2C60-2C6Y] [58]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Lapatinib. Breast cancer [2C60-2C6Y] [48]
Thiotepa DMIZKOP Minor Decreased absorption of Norfloxacin due to intestinal mucosa variation caused by Thiotepa. Breast cancer [2C60-2C6Y] [57]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Bosutinib. Breast cancer [2C60-2C6Y] [50]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [59]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Norfloxacin and Olodaterol. Chronic obstructive pulmonary disease [CA22] [60]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Norfloxacin and Arformoterol. Chronic obstructive pulmonary disease [CA22] [60]
Capecitabine DMTS85L Minor Decreased absorption of Norfloxacin due to intestinal mucosa variation caused by Capecitabine. Colorectal cancer [2B91] [57]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Norfloxacin and Isoproterenol. Conduction disorder [BC63] [54]
Mestranol DMG3F94 Moderate Decreased absorption of Norfloxacin due to formation of complexes caused by Mestranol. Contraceptive management [QA21] [61]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Halothane. Corneal disease [9A76-9A78] [48]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Sevoflurane. Corneal disease [9A76-9A78] [58]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Probucol. Coronary atherosclerosis [BA80] [56]
Oxtriphylline DMLHSE3 Moderate Decreased metabolism of Norfloxacin caused by Oxtriphylline mediated inhibition of CYP450 enzyme. Cough [MD12] [62]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Norfloxacin and Pasireotide. Cushing syndrome [5A70] [58]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Osilodrostat. Cushing syndrome [5A70] [49]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Sertraline. Depression [6A70-6A7Z] [48]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Norfloxacin and Escitalopram. Depression [6A70-6A7Z] [58]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Clomipramine. Depression [6A70-6A7Z] [48]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Doxepin. Depression [6A70-6A7Z] [48]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [58]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Deutetrabenazine. Dystonic disorder [8A02] [63]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Ingrezza. Dystonic disorder [8A02] [64]
Stiripentol DMMSDOY Moderate Decreased metabolism of Norfloxacin caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [50]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Solifenacin. Functional bladder disorder [GC50] [48]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Sunitinib. Gastrointestinal stromal tumour [2B5B] [48]
Procarbazine DMIK367 Minor Decreased absorption of Norfloxacin due to intestinal mucosa variation caused by Procarbazine. Hodgkin lymphoma [2B30] [57]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [65]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Norfloxacin and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [66]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [58]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [48]
Bempedoic acid DM1CI9R Major Increased risk of tendinitis/tendon rupture by the combination of Norfloxacin and Bempedoic acid. Hyper-lipoproteinaemia [5C80] [67]
Melatonin DMKWFBT Minor Decreased metabolism of Norfloxacin caused by Melatonin mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [56]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Norfloxacin caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [68]
Iron DMAP8MV Moderate Decreased absorption of Norfloxacin due to formation of complexes caused by Iron. Iron deficiency anaemia [3A00] [69]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Norfloxacin and Polyethylene glycol. Irritable bowel syndrome [DD91] [58]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Norfloxacin and Phenolphthalein. Irritable bowel syndrome [DD91] [56]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Norfloxacin and Crizotinib. Lung cancer [2C25] [70]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Norfloxacin and Ceritinib. Lung cancer [2C25] [58]
Lurbinectedin DMEFRTZ Minor Decreased absorption of Norfloxacin due to intestinal mucosa variation caused by Lurbinectedin. Lung cancer [2C25] [57]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Norfloxacin and Osimertinib. Lung cancer [2C25] [71]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Norfloxacin and Selpercatinib. Lung cancer [2C25] [72]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Norfloxacin and Lumefantrine. Malaria [1F40-1F45] [56]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Norfloxacin and Halofantrine. Malaria [1F40-1F45] [56]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Norfloxacin and Hydroxychloroquine. Malaria [1F40-1F45] [73]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Primaquine. Malaria [1F40-1F45] [48]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [50]
Fludarabine DMVRLT7 Minor Decreased absorption of Norfloxacin due to intestinal mucosa variation caused by Fludarabine. Malignant haematopoietic neoplasm [2B33] [57]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Norfloxacin and Arsenic trioxide. Mature B-cell lymphoma [2A85] [74]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Norfloxacin and Vemurafenib. Melanoma [2C30] [58]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and LGX818. Melanoma [2C30] [75]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Norfloxacin due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [58]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Norfloxacin and Panobinostat. Multiple myeloma [2A83] [76]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Norfloxacin and Siponimod. Multiple sclerosis [8A40] [56]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Norfloxacin and Fingolimod. Multiple sclerosis [8A40] [58]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Norfloxacin and Ozanimod. Multiple sclerosis [8A40] [77]
Deflazacort DMV0RNS Major Increased risk of tendinitis/tendon rupture by the combination of Norfloxacin and Deflazacort. Muscular dystrophy [8C70] [78]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Romidepsin. Mycosis fungoides [2B01] [56]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Norfloxacin and Nilotinib. Myeloproliferative neoplasm [2A20] [58]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Dasatinib. Myeloproliferative neoplasm [2A20] [48]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Promethazine. Nausea/vomiting [MD90] [48]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Norfloxacin and Bupropion. Nicotine use disorder [6C4A] [79]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Entrectinib. Non-small cell lung cancer [2C25] [50]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Norfloxacin and Levomethadyl Acetate. Opioid use disorder [6C43] [50]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Lofexidine. Opioid use disorder [6C43] [58]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Rucaparib. Ovarian cancer [2C73] [48]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Triclabendazole. Parasitic worm infestation [1F90] [56]
Rasagiline DM3WKQ4 Moderate Decreased metabolism of Norfloxacin caused by Rasagiline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [56]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Pimavanserin. Parkinsonism [8A00] [80]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Norfloxacin and Lefamulin. Pneumonia [CA40] [49]
Choline salicylate DM8P137 Moderate Additive CNS stimulant effects by the combination of Norfloxacin and Choline salicylate. Postoperative inflammation [1A00-CA43] [81]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Degarelix. Prostate cancer [2C82] [50]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Enzalutamide. Prostate cancer [2C82] [50]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Relugolix. Prostate cancer [2C82] [50]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Bicalutamide. Prostate cancer [2C82] [50]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Levomepromazine. Psychotic disorder [6A20-6A25] [56]
Salsalate DM13P4C Moderate Additive CNS stimulant effects by the combination of Norfloxacin and Salsalate. Rheumatoid arthritis [FA20] [82]
Dexamethasone DMMWZET Major Increased risk of tendinitis/tendon rupture by the combination of Norfloxacin and Dexamethasone. Rheumatoid arthritis [FA20] [78]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Quetiapine. Schizophrenia [6A20] [58]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Aripiprazole. Schizophrenia [6A20] [56]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Norfloxacin and Iloperidone. Schizophrenia [6A20] [58]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Paliperidone. Schizophrenia [6A20] [48]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Norfloxacin and Amisulpride. Schizophrenia [6A20] [83]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Asenapine. Schizophrenia [6A20] [58]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Norfloxacin and Pimozide. Schizophrenia [6A20] [50]
Ifosfamide DMCT3I8 Minor Decreased absorption of Norfloxacin due to intestinal mucosa variation caused by Ifosfamide. Solid tumour/cancer [2A00-2F9Z] [57]
Docetaxel DMDI269 Minor Decreased absorption of Norfloxacin due to intestinal mucosa variation caused by Docetaxel. Solid tumour/cancer [2A00-2F9Z] [57]
Mitoxantrone DMM39BF Minor Decreased absorption of Norfloxacin due to intestinal mucosa variation caused by Mitoxantrone. Solid tumour/cancer [2A00-2F9Z] [57]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Norfloxacin and LEE011. Solid tumour/cancer [2A00-2F9Z] [58]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Norfloxacin and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [58]
Taxol DMUOT9V Minor Decreased absorption of Norfloxacin due to intestinal mucosa variation caused by Taxol. Solid tumour/cancer [2A00-2F9Z] [57]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Pitolisant. Somnolence [MG42] [50]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [48]
Plicamycin DM7C8YV Minor Decreased absorption of Norfloxacin due to intestinal mucosa variation caused by Plicamycin. Testicular cancer [2C80] [57]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Lenvatinib. Thyroid cancer [2D10] [48]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Norfloxacin and Cabozantinib. Thyroid cancer [2D10] [50]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Norfloxacin and Papaverine. Tonus and reflex abnormality [MB47] [84]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [56]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Propafenone. Ventricular tachyarrhythmia [BC71] [48]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Norfloxacin and Flecainide. Ventricular tachyarrhythmia [BC71] [48]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Norfloxacin and Amiodarone. Ventricular tachyarrhythmia [BC71] [85]
⏷ Show the Full List of 118 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Carmellose sodium E00625 Not Available Disintegrant
Magnesium stearate E00208 11177 lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Norfloxacin 400 mg tablet 400 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074690.
2 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.
6 Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab Dispos. 2006 Apr;34(4):690-5.
7 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
8 Clinically significant psychotropic drug-drug interactions in the primary care setting. Curr Psychiatry Rep. 2012 Aug;14(4):376-90.
9 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
10 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
11 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
12 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
13 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
14 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
15 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
16 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
17 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
18 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
19 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
20 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
21 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
22 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
23 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
24 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
25 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
26 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
27 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
28 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
29 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
30 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
31 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
32 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
33 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
34 Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9.
35 Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95.
36 Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
37 Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
38 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
39 Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
40 Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
41 Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6.
42 Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
43 Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
44 Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in tar... Antimicrob Agents Chemother. 2002 Feb;46(2):582-5.
45 In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65.
46 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
47 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
48 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
49 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
50 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
51 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
52 Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001): 301-19. [PMID: 11253855]
53 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
54 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
55 Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986): 187-93. [PMID: 3542945]
56 Cerner Multum, Inc. "Australian Product Information.".
57 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
58 Canadian Pharmacists Association.
59 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
60 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
61 Friedman CI, Huneke AL, Kim MH, Powell J "The effect of ampicillin on oral contraceptive effectiveness." Obstet Gynecol 55 (1980): 33-7. [PMID: 7188714]
62 Davis RL, Kelly HW, Quenzer RW, Standefer J, Steinberg B, Gallegos J "Effect of norfloxacin on theophyllin metabolism." Antimicrob Agents Chemother 33 (1989): 212-4. [PMID: 2719466]
63 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
64 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
65 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
66 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
67 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
68 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
69 Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5. [PMID: 2334155]
70 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
71 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
72 Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
73 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
74 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
75 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
76 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
77 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
78 FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
79 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
80 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
81 Davey PG "Overview of drug interactions with the quinolones." J Antimicrob Chemother 22(suppl c) (1988): 97-107. [PMID: 3053579]
82 Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
83 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
84 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
85 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]